Noguchi Y, Nagasawa H, Tachi T, Tsuchiya T, Teramachi H
Pharmazie. 2019 Sep 1;74(9):570-574. doi: 10.1691/ph.2019.9426.
Among the mechanisms responsible for cognitive dysfunction in chronic kidney disease (CKD) are albuminuria and oxidative stress. However, there may be other causes not yet identified. In fact, the full relevance of CKD patient drug use and its relationship to dementia has hardly been barely investigated. We identified drugs affecting cognitive function in CKD patients by analyzing the spontaneous reporting system in Japan using . The signal detection criterion used were as follows: ≥ 3, > 1, > 1 () and >0 (). Drugs with more than 20 cases were valaciclovir (: 11.21, : 1.28, : 3.12), amantadine (: 19.69, : 1.68, : 3.05), nalfurafine (: 8.35, : 1.19, : 2.18), pregabalin (: 6.05, : 1.12, : 1.78), and acyclovir (: 5.89, : 1.12, : 1.68). This study is the first report to use a large-scale medical database to identify drugs related to oral drugs-induced dementia in CKD.
慢性肾脏病(CKD)认知功能障碍的相关机制包括蛋白尿和氧化应激。然而,可能还存在其他尚未明确的原因。事实上,CKD患者用药的全面相关性及其与痴呆症的关系几乎未得到充分研究。我们通过分析日本的自发报告系统,确定了影响CKD患者认知功能的药物。使用的信号检测标准如下:≥3、>1、>1()和>0()。病例数超过20例的药物有伐昔洛韦(:11.21,:1.28,:3.12)、金刚烷胺(:19.69,:1.68,:3.05)、纳呋拉啡(:8.35,:1.19,:2.18)、普瑞巴林(:6.05,:1.12,:1.78)和阿昔洛韦(:5.89,:1.12,:1.68)。本研究是首次使用大规模医学数据库来识别与CKD口服药物所致痴呆相关药物的报告。